Contineum Therapeutics
Logotype for Contineum Therapeutics Inc

Contineum Therapeutics (CTNM) investor relations material

Contineum Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Contineum Therapeutics Inc
Q3 2026 earnings summary3 Nov, 2026

Executive summary

  • PIPE-791 is the lead wholly owned candidate; PROPEL-IPF patient dosing began in Q1 2026, with trial completion targeted for June 2028.

  • J&J’s Phase 2 MOONLIGHT-1 trial of PIPE-307 in major depressive disorder missed its primary endpoint; it was well tolerated, and J&J is reviewing exploratory data before deciding next steps.

  • Cash, cash equivalents and marketable securities totaled $244.5 million at September 30, 2026; management projects funding for planned operations through mid-2029.

Financial highlights

  • Q3 2026 operating expenses were $21.0 million versus $14.9 million YoY; net loss was $18.7 million versus $12.8 million.

  • Q3 R&D expense was $16.0 million, up 45% YoY, primarily from PIPE-791 development and employee-related costs; G&A was $5.0 million, up 26%, mainly from stock compensation and employee costs.

  • 9M 2026 operating expenses were $55.3 million versus $50.9 million; net loss was $48.3 million versus $44.8 million.

  • 9M R&D expense was $40.3 million versus $38.8 million; G&A was $15.0 million versus $12.2 million, with higher stock compensation and personnel costs contributing to the increase.

  • No revenue was recognized in Q3 or 9M 2026; interest income was $2.4 million for Q3 and $7.2 million for 9M.

Outlook and guidance

  • Management expects available cash resources to fund planned operations through mid-2029, one year beyond the estimated completion of the IPF trial.

  • PROPEL-IPF evaluates once-daily oral PIPE-791 over 26 weeks in approximately 324 IPF patients; completion remains targeted for June 2028.

  • Operating expenses, particularly R&D, are expected to increase substantially as clinical development, pipeline work, headcount and public-company activities continue.

  • Future funding may come from equity, debt or commercial arrangements; financing may be unavailable or require dilution or concessions on program rights.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Contineum Therapeutics earnings date

Logotype for Contineum Therapeutics Inc
Stifel 2026 Healthcare Conference 202612 Nov, 2026
Contineum Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Contineum Therapeutics earnings date

Logotype for Contineum Therapeutics Inc
Stifel 2026 Healthcare Conference 202612 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Contineum Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel, oral small molecule therapies. The company focuses on treatments for neuroscience, inflammation, and immunology (NI&I) conditions that have significant unmet medical needs. Contineum is headquartered in San Diego, California, and its shares are listed on the NASDAQ.